Team:Wageningen UR/HumanBody

From 2012.igem.org

Revision as of 10:52, 26 October 2012 by Jjkoehorst (Talk | contribs)

Contents

Human Body Model

To be able to determain what the vlps and the medicine do in the human body we've constructed a human body model that is inspired by the model of the Slovenia 2012 team. With this model we are able to compare the traditional use of medicine with the use of our VLPs. If succesful it will open up a whole new era for the use of medicine.

PICTURE TESTING

VLP1.png VLP2.PNG VLP3.png VLP4.png VLP5.png VLP6.png VLP7.png VLP8.png VLP9.png VLP9.png VLP10.png VLP11.png VLP12.png VLP13.png VLP14.png VLP15.png VLP16.png VLP17.png VLP18.png VLP19.png VLP20.png VLP21.png VLP22.png VLP23.png VLP24.png VLP25.png VLP26.png VLP27.png

Explanation of the model

Our model is constructed in such a way that each compartment of the model represent an organ or multiple organs with the same physical properties. We decided to have separate compartments for the kidneys, liver, lungs and the intestine. All other organs are grouped in the rapid or slowly perfused tissue. In the case study we made a new compartment between the intestine and the liver to represents the intestine tumor. (figure: flow scheme human body)

(figure: flow scheme human body)

In our model we’ve used three different mass balance equations for an organ. The first mass balance describes the concentration of all the VLPs in the organ, this is to see the overall change in the VLP concentration. The second mass balance equation describes the concentration of the unbound VLPs. This is because the unbound particles can move freely into the body while the bound particles stays into the organ. (figure: flow scheme organ) The final mass balance equation is for the concentration of the medicine in the organ. With these three mass balance equation we’ve developed our model

(figure: flow scheme organ)


General mass balance equations for all the VLPs

The equations below describe the change in concentration of all the VLPs in the different organs. The mass balances for the different organs consists out of multiple parts. Each organ as at least an flow that describes the concentration of VLPs that come into the organs and a flow that describes the VLP concentration that goes out of the organ. Also each organ has a rate of decay incorporated into the mass balance to describe the falling apart of the VLPs in the different organs. The mass balance of the kidney has also an equation for the removal of the VLPs via the urinal track.

Rapid perfused tissue VLP2.PNG

Slowly perfused tissue

Liver VLP3.png

Kidney VLP4.png

Intestine Healthy VLP8.png

Intestine Sick (Tumor) VLP9.png

Arterial VLP7.png

Lung VLP6.png

Venous VLP5.png

General mass balance equations for the unbound VLPs

Besides needing an equation to describe the change in concentration of all the VLPs, we also need an equation to describe the change in concentration of the unbound VLPs for each organ. The mass balances for the different organs consists out of multiple parts. The mass balances are similar to the mass balance for all the VLPs, with a slight difference, it’s has a rate of VLP attachment. This rate describes the attachment of the VLPs onto the surface of the cell.

Rapid perfused tissue VLP10.png

Slowly perfused tissue VLP11.png

Liver VLP12.png

Kidney VLP13.png

Intestine Healthy VLP17.png

Intestine Sick (Tumor) VLP18.png

Arterial VLP16.png

Lung VLP15.png

Venous VLP14.png

General mass balance equations for the medicine

The last set of mass balances are for the change of concentration of the medicine in the different organs. These equations consists out of multiple parts, similar to the previous set of mass balances. Each organ as at least an flow that describes the concentration of medicine that come into the organs and a flow that describes the medicine concentration that goes out of the organ. Also each organ has a rate of decay incorporated into the mass balance to describe the decay of medicine in the different organs. The mass balance of the kidney has also an equation for the removal of the medicine via the urinal track.

Rapid perfused tissue VLP19.png

Slowly perfused tissue VLP20.png

Liver VLP23.png

Kidney VLP24.png

Intestine Healthy VLP21.png

Intestine Sick (Tumor) VLP22.png

Arterial VLP27.png

Lung VLP26.png

Venous VLP25.png

Case study: colorectal cancer

As our case study to use the human body model, we used colorectal cancer. Cancer as a disease is very destructive and is responsible for the deaths of millions. In 2007, 13% of all the deaths were cancer related (1). We chose colorectal cancer because in Europe the 5 year survival the disease is less than 60% (2). If our treatment shows a better treatment we can help the people to fight off the cancer.

Treatment of Colorectal cancer

The conventional way to treat colorectal cancer includes surgery and chemotherapy if the cancer is detected in an early stage, when it detected in a later stage treatment is often directed more at extending life and keeping people comfortable (2). The agents used for chemotherapy are fluorouracil, capecitabine, UFT, leucovorin, irinotecan, or oxaliplatin. Side effects of the agents are:

  • Acute central nervous system damage
  • Bone marrow suppression
  • Mucositis, inflammation of the mucus membranes of the GI track
  • Dermatitis, inflammation of the skin
  • Diarrhoea
  • Nausea
  • and many more

We believe, if we can focus the agent around the tumor we’ll able to reduce the side effect and create a better chemotherapy treatment for cancer patients.

Parameters

For the distribution of VLPs throughout the human body, used parameters were obtained from the documentation Slovenia 2012 or from literature sources [1]. The estimated parameters for the organs in table XXX are explained as followed: Blood-flow, the amount of blood in liters flushing throughout the organs, Volumes, the size of the organ, Receptor, the concentration of receptors in µM and the partition coefficient of the medicine that is packaged within the VLP.

Here is the awesome caption
OrganBlood-flow [L/min]Volume [L]Receptor 1 [uM]Partition coefficient medicine
Slowly perfused tissue2.1253.20.237100
Rapidly perfused tissue13.610.237100
Kidney1.060.310.237100
Liver1.41.820.237100
Lung5.580.560.237100
Intestine Healthy0.944.410.237100
Tumor0.10.4910.716100
Arterial5.581.70.237100
Venous5.583.9237100


Parameters that were estimated for non organ variables are found in table 2 and are explained as followed. Affinity constant for receptor, is the binding affinity of the VLPs to the receptor on the cell surface. VLP elimination rate is the half-life of the VLPs. VLP Renal removal rate is the removal rate of the VLPs within the kidneys. Medicine elimination rate is the removal/degradation of the medicine within the human body. The last parameter is the packaging constant which encapsulate the amount of medicine in µmol? within a single VLP.

Here is the awesome caption
Affinity constant for receptor0.001
VLP elimination rate0.000143
VLP Renal removal rate0.000403
Medicine elimination rate0.05
Packaging constant300

Results

Mark/Jasper

Discussion/Conclusion

Mark/Jasper

Remarks

With this model it becomes possible to simulate the VLP and medicine distribution in the human body. However this model, like every model, has it's limitations. In this paragraph we'll discus the limitations and it's possibilities of this model and how we can improve this model.

Important parameters

Like in every model, there are certain parameters that are important to get a simulation that represends the reality. However finding these parameters can be difficult a data can be missing. This is a real limitation in every model, we have to assume parameters that are important, resulting in a biased result. Here below is a list of the parameters that is crucial to our model.

  1. Ratio of receptor concentration between tumor and healthy tissue
  2. Stability of the VLP
  3. Packaging quantity of the VLP
  4. Binding affinity of the VLP to the receptor
  5. Medicine absorption of tumor / healthy cells
  6. Distribution of receptors on cell surface

Possibilities of the model

Even with it's limitations, the model has it's potential. With this model it becomes possible to.....

Future work / MoSCoW

References

Benjamin L. Shneider; Sherman, Philip M. (2008). Pediatric Gastrointestinal Disease. Connecticut: PMPH-USA. pp. 751.